Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cladribine
Drug ID BADD_D00479
Description An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
Indications and Usage For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.
Marketing Status approved; investigational
ATC Code L01BB04; L04AA40
DrugBank ID DB00242
KEGG ID D01370
MeSH ID D017338
PubChem ID 20279
TTD Drug ID D05GJW
NDC Product Code 42658-010; 12502-5406; 0143-9871; 44087-4000; 54893-0115; 76055-0051; 63323-140; 59605-3006; 65129-1260; 76055-0052; 12502-4912; 58623-0037
UNII 47M74X9YT5
Synonyms Cladribine | 2-Chlorodeoxyadenosine | 2-Chloro-2'-deoxyadenosine | 2'-Deoxy-2-chloroadenosine | Leustatin
Chemical Information
Molecular Formula C10H12ClN5O3
CAS Registry Number 4291-63-8
SMILES C1C(C(OC1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thirst08.01.09.021; 14.03.02.0070.000336%Not Available
Thrombocytopenia01.08.01.0020.000917%Not Available
Thrombosis24.01.01.006--Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Tumour lysis syndrome16.32.03.002; 14.05.01.004--
Unintended pregnancy18.08.01.0010.000229%Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Ureteric obstruction20.06.01.005--Not Available
Urethral disorder20.07.01.002--Not Available
Urinary incontinence20.02.02.010; 17.05.01.0080.000489%
Urinary retention20.02.02.0110.000229%
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.0010.001835%
Uterine leiomyoma21.07.02.004; 16.04.02.001--Not Available
Vaginal haemorrhage24.07.03.005; 21.08.01.0010.000856%
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vertigo17.02.12.002; 04.04.01.0030.001605%
Vertigo positional17.02.12.004; 04.04.01.0050.000336%Not Available
Viral infection11.05.04.001--Not Available
Vision blurred06.02.06.007; 17.17.01.010--
Visual impairment06.02.10.0130.000306%Not Available
Vomiting07.01.07.003--
Wheezing22.03.01.009--
Mobility decreased08.01.03.030; 15.03.05.023; 17.02.05.0180.000413%Not Available
Multiple sclerosis relapse17.16.01.0030.013072%Not Available
Acute generalised exanthematous pustulosis12.03.01.005; 11.07.01.018; 10.01.01.034; 23.03.10.0020.000229%Not Available
Localised oedema14.05.06.009; 08.01.07.011; 02.05.04.006--
Brain oedema17.07.02.003; 12.01.10.0100.000153%
Autoimmune thyroiditis10.04.08.006; 05.02.04.0020.000642%Not Available
The 9th Page    First    Pre   9 10 11 12    Next   Last    Total 12 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene